{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T21:01:00Z","timestamp":1791234060623,"version":"4.1.0"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T00:00:00Z","timestamp":1721260800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"UCB Pharma and Amgen Inc."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,9,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Romosozumab, a humanized monoclonal antibody that binds and inhibits sclerostin, produces a marked increase in bone formation with a concomitant decreased bone resorption. This transient rise in bone formation in the first 2 months of treatment is mainly due to an increased modeling-based bone formation. This requires the recruitment and differentiation of osteoblasts, one possibility being a preferential switch in commitment of precursors to osteoblasts over adipocytes. The purpose of this study was to analyze the marrow adiposity in transiliac bone biopsies at months 2 or 12 from the FRAME biopsy sub-study in patients receiving romosozumab or placebo. The total adipocyte area, number, and density were measured on the total cancellous bone area. The size and shape at the individual adipocyte level were assessed including the mean adipocyte area, perimeter, min and max diameters, and aspect ratio. No significant difference in total adipocyte area, number, or density between placebo and romosozumab groups was observed at months 2 and 12, and no difference was observed between 2 and 12\u00a0months. After 2 or 12\u00a0months, romosozumab did not modify the size or shape of the adipocytes. No relationship between the adipocyte parameters and the dynamic parameters of bone formation could be evidenced. In conclusion, based on the analysis of a small number of biopsies, no effect of romosozumab on bone marrow adiposity of iliac crest was identified after 2 and 12\u00a0months suggesting that the modeling-based formation observed at month 2 was not due to a preferential commitment of the precursor to osteoblast over adipocyte cell lines but may result from a reactivation of bone lining cells and from a progenitor pool independent of the marrow adipocyte population.<\/jats:p>","DOI":"10.1093\/jbmr\/zjae118","type":"journal-article","created":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T13:18:43Z","timestamp":1721222323000},"page":"1278-1283","source":"Crossref","is-referenced-by-count":6,"title":["Evaluation of romosozumab\u2019s effects on bone marrow adiposity in postmenopausal osteoporotic women: results from the FRAME bone biopsy sub-study"],"prefix":"10.1093","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5128-7361","authenticated-orcid":false,"given":"Pascale","family":"Chavassieux","sequence":"first","affiliation":[{"name":"Univ Lyon, INSERM, UMR 1033 , F-69008, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Paul","family":"Roux","sequence":"additional","affiliation":[{"name":"Univ Lyon, INSERM, UMR 1033 , F-69008, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesar","family":"Libanati","sequence":"additional","affiliation":[{"name":"UCB Pharma , Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifei","family":"Shi","sequence":"additional","affiliation":[{"name":"Amgen Inc , Thousand Oaks, CA, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Chapurlat","sequence":"additional","affiliation":[{"name":"Univ Lyon, INSERM, UMR 1033 , F-69008, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,7,18]]},"reference":[{"issue":"13","key":"2024090404565506700_ref1","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1096\/fj.05-4221fje","article-title":"Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation","volume":"19","author":"Poole","year":"2005","journal-title":"FASEB J"},{"key":"2024090404565506700_ref2","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.bone.2016.10.019","article-title":"Effects of sclerostin antibodies in animal models of osteoporosis","volume":"96","author":"Ominsky","year":"2017","journal-title":"Bone"},{"issue":"4","key":"2024090404565506700_ref3","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1002\/jbmr.3036","article-title":"Romosozumab improves bone mass and strength while maintaining bone quality in ovariectomized cynomolgus monkeys","volume":"32","author":"Ominsky","year":"2017","journal-title":"J Bone Miner Res"},{"issue":"5","key":"2024090404565506700_ref4","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1056\/NEJMoa1305224","article-title":"Romosozumab in postmenopausal women with low bone mineral density","volume":"370","author":"McClung","year":"2014","journal-title":"N Engl J Med"},{"issue":"16","key":"2024090404565506700_ref5","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis","volume":"375","author":"Cosman","year":"2016","journal-title":"N Engl J Med"},{"issue":"9","key":"2024090404565506700_ref6","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1002\/jbmr.3735","article-title":"Bone-forming and antiresorptive effects of romosozumab in postmenopausal women with osteoporosis: bone histomorphometry and microCT analysis after 2 and 12 months of treatment","volume":"34","author":"Chavassieux","year":"2019","journal-title":"J Bone Miner Res"},{"issue":"6","key":"2024090404565506700_ref7","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1002\/jbmr.2152","article-title":"Tissue-level mechanisms responsible for the increase in bone formation and bone volume by sclerostin antibody","volume":"29","author":"Ominsky","year":"2015","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2024090404565506700_ref8","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/jbmr.4457","article-title":"Modeling-based bone formation after 2\u2009months of romosozumab treatment: results from the FRAME clinical trial","volume":"37","author":"Eriksen","year":"2022","journal-title":"J Bone Miner Res"},{"key":"2024090404565506700_ref9","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.bone.2018.05.019","article-title":"Defining osteoblast and adipocyte lineage in the bone marrow","volume":"118","author":"Pierce","year":"2019","journal-title":"Bone"},{"issue":"2","key":"2024090404565506700_ref10","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/path.1700940205","article-title":"Quantitative histological studies on age changes in bone","volume":"94","author":"Dunnill","year":"1967","journal-title":"J Path Bact"},{"key":"2024090404565506700_ref11","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/00003086-197110000-00021","article-title":"Osteoporosis and the replacement of cell populations of the marrow by adipose tissue","volume":"80","author":"Meunier","year":"1971","journal-title":"Clin Orthop Rel Res"},{"issue":"5","key":"2024090404565506700_ref12","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1210\/er.2018-00138","article-title":"Bone marrow adiposity: basic and clinical implications","volume":"40","author":"Sebo","year":"2019","journal-title":"Endocrine Rev"},{"key":"2024090404565506700_ref13","doi-asserted-by":"crossref","first-page":"770705","DOI":"10.3389\/fcell.2021.770705","article-title":"Bone marrow adipocytes: a critical player in the bone marrow microenvironment","volume":"9","author":"Wang","year":"2021","journal-title":"Front Cell Dev Biol"},{"issue":"3","key":"2024090404565506700_ref14","doi-asserted-by":"crossref","first-page":"285","DOI":"10.3109\/13697137.2015.1126576","article-title":"Influences of teriparatide administration on marrow fat content in postmenopausal women using MR spectroscopy","volume":"19","author":"Yang","year":"2016","journal-title":"Climateric"},{"issue":"9","key":"2024090404565506700_ref15","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1007\/s00198-008-0574-6","article-title":"Effects of estrogen therapy on bone marrow adipocytes in postmenopausal osteoporotic women","volume":"19","author":"Syed","year":"2008","journal-title":"Osteopor Int"},{"issue":"1","key":"2024090404565506700_ref16","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.tem.2008.09.002","article-title":"Adipogenesis and WNT signaling","volume":"20","author":"Christodoulides","year":"2009","journal-title":"Trends Endocrinol Metab"},{"issue":"5481","key":"2024090404565506700_ref17","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1126\/science.289.5481.950","article-title":"Inhibition of adipogenesis by Wnt signaling","volume":"289","author":"Ross","year":"2000","journal-title":"Science"},{"issue":"11","key":"2024090404565506700_ref18","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1002\/jbmr.1694","article-title":"Loss of wnt\/\u03b2-catenin signaling causes cell fate shift of preosteoblasts from osteoblasts to adipocytes","volume":"27","author":"Song","year":"2012","journal-title":"J Bone Miner Res"},{"issue":"2","key":"2024090404565506700_ref19","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1002\/jcp.25976","article-title":"The skeletal cell-derived molecule sclerostin drives bone marrow adipogenesis","volume":"233","author":"Fairfield","year":"2018","journal-title":"J Cell Physiol"},{"key":"2024090404565506700_ref20","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.bone.2019.03.038","article-title":"Inverse correlation between trabecular bone volume and bone marrow adipose tissue in rats treated with osteoanabolic agents","volume":"123","author":"Costa","year":"2019","journal-title":"Bone"},{"key":"2024090404565506700_ref21","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.bone.2016.10.010","article-title":"Sclerostin deficiency in humans","volume":"96","author":"Van Lierop","year":"2017","journal-title":"Bone"},{"key":"2024090404565506700_ref22","doi-asserted-by":"crossref","first-page":"584147","DOI":"10.3389\/fendo.2021.584147","article-title":"Sclerostin and osteocalcin: candidate bone-produces hormones","volume":"12","author":"Wang","year":"2021","journal-title":"Front Endocrinol"},{"issue":"8","key":"2024090404565506700_ref23","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1210\/jc.2012-1477","article-title":"Increased marrow adiposity in premenopausal women with idiopathic osteoporosis","volume":"97","author":"Cohen","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2024090404565506700_ref24","doi-asserted-by":"crossref","DOI":"10.1016\/j.beem.2021.101518","article-title":"Marrow adipogenic lineage precursor: a new cellular component of marrow adipose tissue","volume":"35","author":"Zhong","year":"2021","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"2","key":"2024090404565506700_ref25","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/joim.12718","article-title":"Clinical implications of bone marrow adiposity","volume":"283","author":"Veldhuis-Vlug","year":"2018","journal-title":"J Intern Med"},{"issue":"1","key":"2024090404565506700_ref26","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1210\/en.2013-1712","article-title":"Mechanisms of palmitate-induced lipotoxicity in human osteoblasts","volume":"155","author":"Gunaratnam","year":"2014","journal-title":"Endocrinology"},{"issue":"2","key":"2024090404565506700_ref27","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1007\/s11914-018-0427-y","article-title":"Good, bad, or ugly: the biological roles of bone marrow","volume":"16","author":"Singh","year":"2018","journal-title":"Curr Osteoporos Rep"},{"issue":"4","key":"2024090404565506700_ref28","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1002\/jbmr.4504","article-title":"Saturated and unsaturated bone marrow lipids have distinct effects on bone density and fracture risk in older adults","volume":"37","author":"Woods","year":"2022","journal-title":"J Bone Miner Res"},{"issue":"12","key":"2024090404565506700_ref29","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1002\/stem.2474","article-title":"Quiescent bone lining cells are a major source of osteoblasts during adulthood","volume":"34","author":"Matic","year":"2016","journal-title":"Stem Cells"},{"issue":"6","key":"2024090404565506700_ref30","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1002\/jbmr.4815","article-title":"A critical role of the bone marrow envelope in human bone remodeling","volume":"38","author":"Andersen","year":"2023","journal-title":"J Bone Miner Res"},{"key":"2024090404565506700_ref31","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.bone.2015.12.013","article-title":"Time-dependent cellular and transcriptional changes in osteoblast lineage associated with sclerostin antibody treatment in ovariectomized rats","volume":"84","author":"Taylor","year":"2016","journal-title":"Bone"},{"key":"2024090404565506700_ref32","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.bonr.2018.03.001","article-title":"Decreased osteoprogenitor proliferation precedes attenuation of cancellous bone formation in ovariectomized rats treated with sclerostin antibody","volume":"8","author":"Boyce","year":"2018","journal-title":"Bone Rep"},{"key":"2024090404565506700_ref33","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.bone.2015.08.007","article-title":"Differential temporal effects of sclerostin antibody and parathyroid hormone on cancellous and cortical bone and quantitative differences in effects on the osteoblast lineage in young intact rats","volume":"81","author":"Ominsky","year":"2015","journal-title":"Bone"},{"issue":"5","key":"2024090404565506700_ref34","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1002\/jbmr.3038","article-title":"Sclerostin antibody administration converts bone lining cells into active osteoblasts","volume":"32","author":"Kim","year":"2017","journal-title":"J Bone Miner Res"},{"issue":"5","key":"2024090404565506700_ref35","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s00223-022-01013-8","article-title":"Reactivation of bone lining cells are attenuated over repeated anti-sclerostin antibody administration","volume":"111","author":"Hong","year":"2022","journal-title":"Calcif Tissue Int"}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jbmr\/advance-article-pdf\/doi\/10.1093\/jbmr\/zjae118\/58795447\/zjae118.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/39\/9\/1278\/58994118\/zjae118.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/39\/9\/1278\/58994118\/zjae118.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T11:28:18Z","timestamp":1725449298000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/39\/9\/1278\/7716354"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,18]]},"references-count":35,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,7,18]]},"published-print":{"date-parts":[[2024,9,2]]}},"URL":"https:\/\/doi.org\/10.1093\/jbmr\/zjae118","relation":{},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,9]]},"published":{"date-parts":[[2024,7,18]]}}}